Jiri Damborsky and Team: Thrombolytic Proteins Profiling: High-Throughput Activity, Selectivity, And Resistance Assays
Jiri Damborsky, Head of Research Group at ICRC, Loschmidt Laboratories and Masaryk University, posted on LinkedIn:
”STROKE – Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Published: October 4, 2025, FEBS Open Bio.
Read here.
We introduce optimized high-throughput assays for rapid and reliable screening of thrombolytic enzymes – enabling detailed insights into activity, fibrin selectivity, and inhibition resistance.
Cardiovascular and thrombotic diseases remain one of the world’s top health challenges. In our latest work, we introduce a comprehensive set of high-throughput biochemical assays that enable robust screening and detailed characterization of thrombolytic biomolecules – including activity, fibrin selectivity, clot binding, and inhibition resistance.
Using alteplase and tenecteplase as model enzymes, we demonstrate how these assays can accelerate the development of safer and more effective thrombolytic drugs. Our results confirm that tenecteplase outperforms alteplase in fibrin selectivity and inhibition resistance, supporting its growing clinical relevance.”
Title: Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Authors: Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Stay informed with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic